MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Liraglutide Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Liraglutide is a once-daily GLP-1 receptor agonist (Novo Nordisk code NN2211) sold as Victoza for type 2 diabetes and Saxenda for chronic weight management. An acylated analogue of human GLP-1, it binds albumin via a C16 fatty-acid chain to extend its half-life to about 13 hours, enabling daily subcutaneous dosing (PMID 26132939). It lowers glucose by enhancing glucose-dependent insulin secretion and suppressing glucagon, slows gastric emptying, and acts on hypothalamic appetite centers to reduce food intake. Weight-management dosing titrates weekly from 0.6 mg to 3.0 mg/day; glycemic dosing caps at 1.8 mg/day. In SCALE, 3.0 mg produced about 8% weight loss versus 2.6% with placebo (PMID 26132939), and in LEADER it reduced major cardiovascular events in high-risk diabetes (PMID 27295427). As a daily agent it is distinct from weekly semaglutide and tirzepatide. It is FDA- and EMA-approved; research-grade vials are for laboratory use only.
Reconstitute: Add 1.5 mL bacteriostatic water → 10 mg/mL concentration.
Typical dose: 0.6–3.0 mg once daily (Saxenda); max 1.8 mg once daily (Victoza)
Easy measuring: At 10 mg/mL, 1 unit = 0.01 mL = 0.1 mg (100 mcg) on a U-100 insulin syringe.
Storage: Lyophilized vial: refrigerate 2–8°C, protect from light. Reconstituted solution: store at 2–8°C and use within ~14–28 days. Commercial pens: unused refrigerated 2–8°C; in-use stored ≤30°C or refrigerated for up to 30 days.
Half-life: ~13 hours (range 11–15 h); ~55% subcutaneous bioavailability, Tmax 8–12 h, steady state ~3 days
Route: Subcutaneous, once daily (abdomen, thigh, or upper arm), any time of day with or without food
Status: FDA/EMA-approved — Victoza (T2D, 2010) and Saxenda (weight management, 2014); research vials are lab-use only
About Liraglutide
Liraglutide is an acylated GLP-1 receptor agonist given as a once-daily subcutaneous injection. Unlike many compounds catalogued on this site, its real-world clinical route genuinely is subcutaneous, so the reconstitution figures below map directly onto how the drug is actually used [7][8]. Commercially it ships as a prefilled multi-dose pen at 6 mg/mL (Victoza, Saxenda); the vial-and-bacteriostatic-water protocol shown here is an educational reconstitution reference for research-grade lyophilized powder.\n\nThe established Liraglutide dosage uses a deliberately slow weekly escalation to limit gastrointestinal side effects. Weight-management protocols start at 0.6 mg/day and step up by 0.6 mg each week through 1.2, 1.8 and 2.4 mg to a 3.0 mg/day maintenance dose, while glycemic (Victoza) protocols stop at 1.2 mg/day or a maximum of 1.8 mg/day [1][7][8]. Its ~13-hour half-life supports stable once-daily exposure, with steady state reached after about three days of consistent dosing [6].\n\nReconstituting a 15 mg vial with 1.5 mL of bacteriostatic water yields a 10 mg/mL solution, so 0.6 mg measures 6 units and 3.0 mg measures 30 units on a U-100 insulin syringe — every titration step lands on a clean, measurable mark.\n\nFrequency: Inject once daily subcutaneously, at any time of day, with or without food; pick a consistent time each day to aid adherence [7].
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 1.5 mL of bacteriostatic water into a sterile syringe (this yields a 10 mg/mL solution from a 15 mg vial).
Inject the water slowly down the inner wall of the vial; do not spray directly onto the powder and avoid foaming.
Gently swirl or roll the vial until fully dissolved and clear — do not shake, as agitation can denature the peptide.
Load a U-100 insulin syringe to the units for your titration step (0.6 mg = 6 units, 1.2 mg = 12, 1.8 mg = 18, 2.4 mg = 24, 3.0 mg = 30 units).
Swab the site (abdomen, thigh, or upper arm), inject subcutaneously, rotate sites daily, and return the vial to the refrigerator.
Interactive Liraglutide Syringe Calculator
Currently visualizing the 15 mg vial reconstituted with 1.5 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 15mg dry powder in 1.5mL water yields 10.00 mg/mL. To evaluate a 250mcg dose, pull to 2.5 units (3 syringe ticks).
U-100 Syringe Representation
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Phase | Dose per injection | Units (per injection) |
|---|---|---|
| Week 1 — initiation (0.6 mg/day) | 600 mcg | 6 units (0.06 mL) |
| Week 2 — escalation (1.2 mg/day; Victoza step dose) | 1200 mcg (1.2 mg) | 12 units (0.12 mL) |
| Week 3 — Victoza glycemic ceiling (max 1.8 mg/day) | 1800 mcg (1.8 mg) | 18 units (0.18 mL) |
| Weeks 4→5+ — Saxenda titration to maintenance (week 4 = 2.4 mg, week 5+ = 3.0 mg/day) | 3000 mcg (3 mg) | 30 units (0.30 mL) |
Administration guidelines: Refer to guidelines | 1.5 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 15 mg vial.
Peptide Vials (Liraglutide, 15 mg each):
- check8 weeks (0.6→3.0 mg/day titration): ~126 mg total ≈ 9 vials
- check12 weeks (to 3.0 mg/day maintenance): ~210 mg total ≈ 14 vials
- check16 weeks (to 3.0 mg/day maintenance): ~294 mg total ≈ 20 vials
Insulin Syringes (U-100):
- check8 weeks: 56 syringes (1 per daily injection)
- check12 weeks: 84 syringes
- check16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles): Use 1.5 mL per vial for reconstitution.
- check8 weeks (9 vials): ~14 mL → 2 × 10 mL bottles
- check12 weeks (14 vials): ~21 mL → 3 × 10 mL bottles
- check16 weeks (20 vials): ~30 mL → 3 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- checkPer day: 2 swabs (vial stopper + injection site)
- check8 weeks: ~112 swabs → 1 × 200-count box
- check12 weeks: ~168 swabs → 2 × 100-count boxes
- check16 weeks: ~224 swabs → 3 × 100-count boxes
Mechanism of Action (MOA)
Liraglutide is a 97%-homologous analogue of native human glucagon-like peptide-1 (GLP-1 7-37). Two engineering changes convert the rapidly degraded native hormone — whose half-life is only about 1–2 minutes — into a once-daily drug: an Arg34→Lys substitution and attachment of a 16-carbon palmitoyl fatty-acid chain to Lys26 through a glutamic-acid spacer. The fatty-acid tail promotes self-association into heptamers at the injection depot and reversible, high-affinity binding to serum albumin (>98%), which together slow absorption and shield the peptide from dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidase degradation [6][9].\n\nAs a GLP-1 receptor agonist, liraglutide reproduces the incretin effect. At pancreatic beta cells it stimulates glucose-dependent insulin secretion and suppresses inappropriate glucagon release, lowering blood glucose with low intrinsic hypoglycemia risk because the effect attenuates as glucose normalizes [3][9]. In the gut it slows gastric emptying, blunting post-prandial glucose excursions. Centrally, it acts on the hypothalamus and brainstem, activating POMC/CART neurons while indirectly inhibiting orexigenic AgRP/NPY signaling in the arcuate nucleus, which reduces hunger, increases satiety and lowers energy intake — the rationale for the higher 3.0 mg weight-management dose [1][9].\n\nPharmacokinetically, subcutaneous liraglutide has an absolute bioavailability of approximately 55%, reaches peak plasma concentration (Tmax) at about 8–12 hours, and has a terminal half-life of roughly 13 hours (range 11–15 h), an exposure profile well suited to once-daily dosing [6]. Steady state is reached after about three days of consistent injection. The molecule is metabolized endogenously like a large protein, with no single organ identified as a major elimination route; no intact liraglutide is recovered in urine or feces, so no dose adjustment is required for mild-to-moderate renal or hepatic impairment [6][7].\n\nThe weekly +0.6 mg titration is pharmacodynamically deliberate: gastrointestinal tolerance improves with gradual receptor adaptation, so the five-step climb to 3.0 mg (Saxenda) or the shorter climb to 1.2–1.8 mg (Victoza) markedly reduces nausea and vomiting versus immediate high dosing [1][7][8]. Downstream, sustained agonism produces dose-dependent weight loss, HbA1c reductions of roughly 1.0–1.5%, modest systolic blood-pressure and triglyceride reductions, and — uniquely demonstrated in the LEADER outcomes trial — a reduction in cardiovascular death and major adverse cardiovascular events in high-risk type 2 diabetes [2][3]. Because the drug is daily rather than weekly, a missed dose clears within about 2–3 days; if dosing lapses beyond three days the manufacturer advises re-initiating at the lowest dose and re-titrating [7].
Clinical Trial Efficacy Highlights
- starSCALE Obesity and Prediabetes (Pi-Sunyer et al., NEJM 2015) randomized 3,731 adults with a BMI ≥30 (or ≥27 with comorbidity) and without diabetes to liraglutide 3.0 mg/day or placebo for 56 weeks. Liraglutide produced an 8.0% mean body-weight reduction versus 2.6% with placebo (treatment difference −5.4%), and 63.2% of the active arm lost at least 5% of body weight versus 27.1% on placebo [1].
- starSCALE Diabetes (Davies et al., JAMA 2015) enrolled 846 overweight/obese adults with type 2 diabetes. Liraglutide 3.0 mg produced roughly 6.0% weight loss versus about 2.0% with placebo at 56 weeks, with more than a quarter of treated patients losing over 10% of body weight, while also improving glycemic control [3].
- starLEADER (Marso et al., NEJM 2016) followed 9,340 adults with type 2 diabetes at high cardiovascular risk for a median 3.8 years. Liraglutide cut the primary composite of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke by 13% (HR 0.87), reduced cardiovascular death by 22% and all-cause mortality by 15% — the first GLP-1 agonist to demonstrate cardiovascular benefit in a dedicated outcomes trial [2].
- starSCALE Maintenance (Wadden et al., Int J Obes 2013) showed that after low-calorie-diet-induced weight loss, liraglutide 3.0 mg drove an additional 6.2% mean weight reduction versus 0.2% with placebo, and 81.4% of liraglutide recipients maintained their initial ≥5% loss versus 48.9% on placebo — supporting its role in preventing weight regain [4].
- starELLIPSE (Tamborlane et al., NEJM 2019) randomized 134 children and adolescents (ages 10 to <17) with type 2 diabetes to liraglutide (up to 1.8 mg/day) plus metformin or placebo. HbA1c fell by 0.64% with liraglutide but rose 0.42% with placebo (difference −1.06%) at 26 weeks, establishing efficacy in pediatric type 2 diabetes, albeit with more gastrointestinal adverse events [5].
- starPharmacokinetic and pharmacodynamic characterization (Jacobsen et al., Clin Pharmacokinet 2016) confirms approximately 55% subcutaneous bioavailability, a Tmax near 8–12 hours, a ~13-hour terminal half-life and steady state by about day 3, with exposure roughly dose-proportional — the basis for predictable once-daily titration and the absence of renal/hepatic dose adjustments [6].
- starAcross the Victoza glycemic program, liraglutide 1.2–1.8 mg/day lowered HbA1c by roughly 1.0–1.5% from baseline and reduced body weight and systolic blood pressure, supporting its approval for type 2 diabetes and, on the strength of LEADER, an additional indication to reduce major adverse cardiovascular events [2][8].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningGastrointestinal effects are the most common adverse events: in SCALE roughly 39% of liraglutide 3.0 mg recipients reported nausea, about 15% vomiting, with diarrhea, constipation, dyspepsia and decreased appetite also frequent. Most were mild-to-moderate, peaked during the 4–5 week titration, and improved over time [1][7].
- warningSymptoms are minimized by the slow weekly +0.6 mg escalation; manufacturers advise delaying a dose increase by an extra week (or stepping back down) if a titration step is not tolerated, and maintaining hydration to offset fluid losses [7].
- warningLiraglutide carries an FDA boxed warning for thyroid C-cell tumors based on rodent carcinogenicity studies; it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). A causal link in humans has not been established [7][8].
- warningAcute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing cases, has been reported post-marketing. Patients with persistent severe abdominal pain should stop the drug and be evaluated; it should not be restarted if pancreatitis is confirmed [7].
- warningRapid weight loss increases the risk of cholelithiasis and acute cholecystitis; gallbladder events were more frequent on liraglutide than placebo in the SCALE program [7].
- warningHypoglycemia is uncommon with monotherapy because insulin release is glucose-dependent, but risk rises substantially when liraglutide is combined with sulfonylureas or insulin, which often require dose reduction [3][8].
- warningOther reported effects include a mean heart-rate increase of about 2–3 beats per minute, acute kidney injury secondary to dehydration from severe GI losses, injection-site reactions, gallstone-related symptoms, and rare hypersensitivity reactions [7].
- warningRegulatory status: liraglutide is an FDA- and EMA-approved prescription medicine (Victoza, Saxenda). Research-grade lyophilized vials are sold strictly for laboratory use and are not a substitute for a prescribed, pharmaceutical-quality product; the reconstitution protocol here is educational and is not medical advice.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Liraglutide dosage?expand_more
For chronic weight management (Saxenda) the typical Liraglutide dosage titrates once daily over five weeks: 0.6 mg in week 1, then 1.2, 1.8 and 2.4 mg in successive weeks, reaching a 3.0 mg/day maintenance dose by week 5. For type 2 diabetes glycemic control (Victoza) dosing starts at 0.6 mg/day for one week, increases to 1.2 mg/day, and may go to a maximum of 1.8 mg/day. The weekly +0.6 mg steps exist to reduce nausea; a step can be delayed if a dose is not tolerated.
Is Liraglutide FDA approved?expand_more
Yes. Liraglutide was first FDA-approved as Victoza for type 2 diabetes in 2010 (with an added indication in 2017 to reduce major adverse cardiovascular events), and as Saxenda for chronic weight management in December 2014; Saxenda is also approved for adolescents 12 and older meeting weight criteria. It is likewise approved by the EMA. Note that research-grade lyophilized vials are sold for laboratory use only and are not FDA-approved pharmaceutical products.
What is the half-life of Liraglutide?expand_more
Liraglutide has a terminal half-life of approximately 13 hours (reported range 11–15 hours). Its albumin-binding fatty-acid chain slows absorption and resists DPP-4 degradation, extending exposure far beyond native GLP-1 (about 1–2 minutes). Peak plasma concentration occurs around 8–12 hours after a subcutaneous dose, absolute bioavailability is roughly 55%, and steady state is reached after about three days of once-daily dosing.
How do you reconstitute Liraglutide from a research vial?expand_more
Draw 1.5 mL of bacteriostatic water and inject it slowly down the wall of a 15 mg vial to make a 10 mg/mL solution. Swirl gently until clear — never shake. On a U-100 insulin syringe, 0.6 mg = 6 units, 1.2 mg = 12 units, 1.8 mg = 18 units, 2.4 mg = 24 units and 3.0 mg = 30 units. Store reconstituted solution at 2–8°C and use it within about 14–28 days. Commercially, liraglutide instead comes as a ready-to-use 6 mg/mL pen.
Can Liraglutide be stacked with other GLP-1 drugs like semaglutide or tirzepatide?expand_more
No. Liraglutide should not be combined with semaglutide, tirzepatide, exenatide or any other GLP-1/incretin agent — they act on overlapping receptors, so stacking sharply increases gastrointestinal toxicity, hypoglycemia risk (especially with sulfonylureas or insulin) and pancreatitis risk without proven added benefit. Liraglutide is a daily agent, whereas semaglutide and tirzepatide are weekly; clinicians transition between agents rather than overlapping them. Any change should be supervised by a prescriber.
Related Guides & Tools
Step-by-step references for reconstituting, measuring, and storing Liraglutide, plus the universal dosing calculator.
Academic References & Study Citations
Pi-Sunyer X, Astrup A, Fujioka K, et al. (2015) N Engl J Med 373(1):11-22. 'A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management' (SCALE Obesity and Prediabetes). 8.0% mean weight loss vs 2.6% placebo at 56 weeks. View Scientific Paper →
Marso SP, Daniels GH, Brown-Frandsen K, et al. (2016) N Engl J Med 375(4):311-322. 'Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes' (LEADER). 13% reduction in major adverse cardiovascular events. View Scientific Paper →
Davies MJ, Bergenstal R, Bode B, et al. (2015) JAMA 314(7):687-699. 'Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes' (SCALE Diabetes). View Scientific Paper →
Wadden TA, Hollander P, Klein S, et al. (2013) Int J Obes (Lond) 37(11):1443-1451. 'Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss' (SCALE Maintenance). View Scientific Paper →
Tamborlane WV, Barrientos-Pérez M, Fainberg U, et al. (2019) N Engl J Med 381(7):637-646. 'Liraglutide in Children and Adolescents with Type 2 Diabetes' (ELLIPSE). View Scientific Paper →
Jacobsen LV, Flint A, Olsen AK, Ingwersen SH. (2016) Clin Pharmacokinet 55(6):657-672. 'Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics'. View Scientific Paper →
FDA Prescribing Information — Saxenda (liraglutide) injection 3 mg, Novo Nordisk, 2020. Boxed warning, dosing/titration, and safety. View Scientific Paper →
FDA Prescribing Information — Victoza (liraglutide) injection, Novo Nordisk, 2017. Type 2 diabetes dosing (max 1.8 mg/day) and cardiovascular indication. View Scientific Paper →
Collins L, Costello RA. Glucagon-like Peptide-1 Receptor Agonists / Liraglutide. StatPearls [Internet]. NCBI Bookshelf, updated 2024. View Scientific Paper →